Shorts’ Managing Partner takes seat on global board
Housing provider launches tree replacement programme
East Midlands entrepreneurs hold back as local start-ups plummet
Peak District National Park Authority shares significant restructure proposals under financial pressures
Rolls-Royce signs engine agreement with STARLUX Airlines
Planning approval secured for new Public Mortuary in Northampton
Construction commences on over 100,000 sq ft of industrial premises and employee facilities at Silverstone Park
The Nottinghamshire Golf and Country Club acquired by UK’s largest country club operator
West Northamptonshire Council to pursue South Midlands devolution bid
Derbyshire biotech company makes key appointment
Derbyshire biotech company N4 Pharma has appointed Dr Alastair Smith as an independent Non-Executive Director.
Alastair was the founder and former Chief Executive Officer of Avacta Group, an AIM-listed biotech company established as a spin-out from Leeds University in 2005 and listed on the London Stock Exchange AIM market in 2006.
Over his tenure, Avacta grew into one of the leading AIM biotech companies comprising two divisions: a clinical stage oncology drug company and a diagnostics business.
Alastair joins the company’s remuneration and audit committees.
Nigel Theobald, Chief Executive Officer, N4 Pharma, said: “We are delighted to welcome Alastair to the Board of N4 Pharma. His experience in having founded and grown a start-up to become one of the UK’s leading life science businesses will be invaluable in supporting the commercialisation of Nuvec® and advancing our pipeline of innovative therapies.”
The news comes as David Templeton retires as a Director of the company.Nigel added: “On behalf of my fellow Directors and everyone involved with N4 Pharma, I would like to thank David for all he has contributed over his years with the Company. Whilst he will be sorely missed, his work on dual loading of Nuvec® and its potential for oral delivery has left us with a true point of difference and a clear path towards Phase 1 clinical trials. We wish him all the best for the future.”
Alastair Smith said: “I am delighted to be joining the Board of N4 Pharma. I see strong parallels between N4 Pharma and Avacta; both building a pipeline of therapies that are strongly differentiated by a proprietary platform technology and offer additional opportunities for early commercialisation through licensing.”
Grantham day nursery sold to care home operator
Ghosting is not just a dating phenomenon: by James Pinchbeck, partner at Streets Chartered Accountants
2025 Business Predictions: Daniel McNerney, Managing Director, See Limited
Mortgage and Finance Arena finds new home for 2025
Nottinghamshire-based soft home furnishings company set to enter administration
Nottingham software company named top for AI
Businesses’ profit growth to stall following rising employment costs announced in Autumn Budget
EMEC strengthens team with strategic ecologist appointment
Financial services optimism falls
- Optimism in December, compared with three months ago, fell at the fastest pace since September 2022 (weighted balance of -28% from -13% in September).
- Growth in business volumes picked up in the quarter to December (+32%) after a modest increase in the three months to September (+6%). Firms expect a similarly quick pace of volumes growth over the next three months (+32%).
- Average spreads fell at a survey-record pace in the quarter to December (-62% from -55% in September) and are expected to decline at a slightly slower rate over the next three months (-57%).
- The value of non-performing loans increased in the quarter to December (+18% from 16% in September) at the fastest rate since March 2021. Their value is expected to rise at a broadly similar pace over the next quarter (+21%).
- Profitability fell at a more modest pace in the quarter to December (-14% from -43% in September). FS firms expect a significantly quicker drop in profitability over the next three months (-55%).
- Headcount declined at a quicker rate in the quarter to December (-25% from -15% in September). Firms expect headcount to fall at a similar pace next quarter (-26%).
- Firms expect to increase IT investment in the next 12 months (compared to the last 12). However, capital expenditures on land & buildings and vehicles, plant & machinery are expected to fall.
- Around two-thirds of firms reported that “other” factors were likely to limit capital expenditure over the next 12 months (65%, near last quarter’s record high of 66%). Comments highlighted that companies are most concerned about the impact of substantial cost increases from the Autumn Budget on investment.